Reckitt Says Suboxone 'Product-Hopping' Didn't Harm Buyers
By Matt Fair · September 17, 2014, 6:09 PM EDT
Reckitt Benckiser Group PLC's move to discontinue Suboxone tablets, in lieu of a new dissolving-film version of the opiate addiction treatment, presented no antitrust injury for classes of purchasers who claim...
To view the full article, register now.